within Pharmacolibrary.Drugs.ATC.B;

model B01AB07
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 0.9,
    Cl             = 0.06333333333333332,
    adminDuration  = 600,
    adminMass      = 3.2,
    adminCount     = 1,
    Vd             = 0.0043,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.0,
    Tlag           = 0
  );

  annotation(Documentation(
    info ="<html><body><p>Parnaparin is a low molecular weight heparin (LMWH) used for prophylaxis and treatment of deep vein thrombosis and other thromboembolic disorders. LMWHs like parnaparin act by potentiating the activity of antithrombin III, inhibiting clotting factor Xa. Parnaparin is not widely used today and is not as commonly available or approved in major markets as other LMWHs such as enoxaparin.</p><h4>Pharmacokinetics</h4><p>Estimated pharmacokinetic parameters in adult patients; no published human PK model data found for parnaparin. The values presented are analogical to other subcutaneously administered LMWHs.</p><h4>References</h4><ol><li><p>Frampton, JE, &amp; Faulds, D (1994). Parnaparin. A review of its pharmacology, and clinical application in the prevention and treatment of thromboembolic and other vascular disorders. <i>Drugs</i> 47(4) 652–676. DOI:<a href=&quot;https://doi.org/10.2165/00003495-199447040-00007&quot;>10.2165/00003495-199447040-00007</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/7516862/&quot;>https://pubmed.ncbi.nlm.nih.gov/7516862</a></p></li><li><p>Camporese, G, et al., &amp; Noventa, F (2009). Update on the clinical use of the low-molecular-weight heparin, parnaparin. <i>Vascular health and risk management</i> 5 819–831. DOI:<a href=&quot;https://doi.org/10.2147/vhrm.s3430&quot;>10.2147/vhrm.s3430</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/19851520/&quot;>https://pubmed.ncbi.nlm.nih.gov/19851520</a></p></li><li><p>McKeage, K, &amp; Keating, GM (2008). Parnaparin : a review of its use in the management of venous thromboembolism, chronic venous disease and other vascular disorders. <i>Drugs</i> 68(1) 105–122. DOI:<a href=&quot;https://doi.org/10.2165/00003495-200868010-00007&quot;>10.2165/00003495-200868010-00007</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/18081375/&quot;>https://pubmed.ncbi.nlm.nih.gov/18081375</a></p></li></ol></body></html>",
    revisions = "<html><body><ul><li>06/2025 model generated by LLM gpt-4.1, references by scholarly and scripts created by Tomas Kulhanek</li></ul></body></html>"
  ));
end B01AB07;
